WONCA研究論文摘要匯編_腹主動脈瘤血管內(nèi)修復(fù)與開放修復(fù)的對照研

1、WONCA研究論文摘要匯編_腹主動脈瘤血管內(nèi)修復(fù)與開放修復(fù)的對照研        J. DiabetesCare, 2008, 31 (1): 12-54.    3Buchanan TA, Xiang AH. Gestational diabetesmellitus J. J ClinInvest, 2005, 115 (3): 485-491.    4Metzger BE. Hyperglycemia and adverse pregnancy outcome

2、s J. NEngl JMed, 2008, 358 (19): 1991-2002.    5RatnerRE, Christophi CA, Boyd E. Prevention of diabetes in womenwith a history of gestational diabetes: effects ofmetformin and lifestyleinterventions J. J Clin EndocrinolMetab, 2008, 93 (12): 4774-4779.    6Kim C, Newton

3、KM, Knopp RH. Gestational diabetes and the inci-dence of type 2 diabetes: a systematic review J. Diabetes Care,2002, 25 (10): 1862-1868.    7Fetita L-S, SobngwiE, SerradasP, et a.l Consequences of fetal ex-posure tomaternal diabetes in offspring J. JClin EndocrinolMetab,2006, 91 (10):

4、 3718-3724.    8LangerO. Oral hypoglycemic agents and the pregnant diabetic: " frombench to bedside" J. Semin Perinato,l 2002, 26 (3): 215-224.    9Challier JC, Hauguel S, DesmaizieresV. Effect of insulin on glucoseuptake and metabolism in the human placenta J

5、. J Clin EndocrinolMetab, 1986, 62 (5): 803-807.    10Koren G. Glyburide and fetal safety; transplacental pharmacokineticconsiderations J. Reprod Toxico,l 2001, 15 (3): 227-229.    11MorettiME, RezvaniM, Koren G. Safety of glyburide for gestationaldiabetes: ameta-analys

6、is ofpregnancy outcomes J. Ann Pharma-cother, 2008, 42 (4): 483-490.    12ViswanathanM, Siega-RizAM, MoosMK, et a.l Outcomes ofma-ternalweight gain J. Evid Rep Technol Assess ( Full Rep),2008, (168): 221-223.    13Charles B, NorrisR, Xiao X, et a.l Population pharmacoki

7、netics ofmetformin in late pregnancy J. The DrugMonit, 2006, 28 (1):67-72.    14CoetzeeEJ, JacksonWP. Pregnancy in established non-insulin-de-pendentdiabetics. A five-and-a-half year study atGroote SchuurHospital J. SAfrMed J, 1980, 58 (20): 795-802.    15Coetzee EJ, Ja

8、ckson WP. Oral hypoglycaemics in the first trimesterand fetal outcome J. SAfrMed J, 1984, 65 (16): 635-637.    16Gutzin SJ, KozerE, Magee LA, et a.l The safety of oral hypoglyce-mic agents in the first trimester of pregnancy: ameta-analysis J.    Can JClin Pharmaco,l 20

9、03, 10 (4): 179-183.    17GilbertC, ValoisM, KorenG. Pregnancy outcome after first-trimes-ter exposure to metformin: a meta - analysis J. Fertil Steri,l2006, 86 (3): 658-663.    18張金華,馮玉欣,裴薇,等·二甲雙胍臨床應(yīng)用研究新進(jìn)展J.疑難病雜志, 2009, 8 (12): 767.    19Hoffman L,

10、Nolan C, W ilson JD, eta.l Gestationaldiabetesmellitus-managementguidelines. TheAustralasianDiabetes in PregnancySo-ciety J. Med JAust, 1998, 169 (2): 93-97.    20Higgins JPT, Altman DG. Assessing risk of bias in included studiesM /OL /Higgins JPT, Green S. Cochrane handbook for syste

11、maticreviews of interventions versions 5. 0. 0 (updated February 2008).    The Cochrane Collaboration, 2008. Available from www. cochrane-handbook. org.    21HagueWM, Davoren PM, Oliver J, eta.l Contraindications to use ofmetformin. Metformin may be useful in gestationa

12、l diabetes J.    BMJ, 2003, 326 (7392): 762.    22Rowan JA, HagueWM, GaoW, et a.l Metformin versus insulin forthe treatment ofgestationaldiabetes J. TheNew England Journal ofMedicine, 2008, 358 (19): 2003-2015.    23Moore L, Clokey D, Robinson A. A random

13、ized trial ofmetformincompared to glyburide in the treatmentofgestationaldiabetes J. A-merican Journal of Obstetrics and Gynecology, 2005, 193 (6 Sup-pl): S92.    24MooreLE, BrieryCM, ClokeyD, eta.l Metformin and insulin in themanagement of gestational diabetes mellitus: preliminary r

14、esults of acomparison J. The Journal of Reproductive Medicine, 2007, 52(11): 1011-1015.    25Carpenter MW. Gestational diabetes, pregnancy hypertension, andlate vascular disease J. Diabetes Care, 2007, 30 (Suppl 2):S246-S250.    26McCarthy EA, WalkerSP, McLachlanK, eta.

15、l Metformin in obstet-ric and gynecologic practice: a review J. Obstet Gynecol Surv,2004, 59 (2): 118-127.       【摘要】背景有關(guān)腹主動脈瘤血管內(nèi)修復(fù)與開放修復(fù)對照研究報(bào)道很少。方法本研究將英國37家醫(yī)院19992004年1 252例大腹主動脈瘤(直徑5·5 cm)患者隨機(jī)分組:血管內(nèi)修復(fù)組和開放修復(fù)組,每組626例患者。跟蹤至2009年末,觀察患者的死亡、移植相關(guān)并發(fā)癥、再干預(yù)發(fā)生率和資源使用情況,采用邏輯回歸和COX回歸法比較兩組結(jié)果。結(jié)果30 d手術(shù)死亡率:血管內(nèi)修復(fù)組為1·8%,開放修復(fù)組為4·3%;與開放修復(fù)組比較,血管內(nèi)修復(fù)組校正優(yōu)勢比為0·39, 95%CI (0·18, 0·87),P=0·02。關(guān)于動脈瘤相關(guān)死亡率,血管內(nèi)修復(fù)組有早期獲益,但研究末期獲益丟失,部分原因?yàn)橹旅郧粌?nèi)移植物破裂校正危害比=0·92, 95% CI (0·57, 1·49),P=0·73。跟蹤末期,兩組全因死亡率比較差